Literature DB >> 21951693

Viscosupplementation in haemophilic arthropathy: a long-term follow-up study.

C Carulli1, R Civinini, C Martini, S Linari, M Morfini, M Tani, M Innocenti.   

Abstract

Haemophilic arthropathy is the most common clinical manifestation of haemophilia, secondary to recurrent haemarthroses and chronic synovitis. Modern bleeding-preventing drugs have limited significantly the incidence of severe arthropathy, and primary approach is usually conservative. Use of intra-articular injections of hyaluronan acid is considered one of the most efficient treatments for early stages of articular degenerative diseases. Assessment of long-term effectiveness of intra-articular administration of hyaluronic acid (HA) in knees, ankles and elbows of patients affected by haemophilic arthropathy was done for 46 patients (10 elbows, 24 knees and 25 ankles) affected by haemophilic arthropathy. They received injections of HA and were evaluated with Visual Analogue Scale, Short Form-36, World Federation of Haemophilia score and Petterson score with a 6-year mean follow-up. Most of the patients showed improvement in pain relief and functional recovery without any complications: only a limited number of patients (8.6%) found poor results, undergoing surgery or other further treatments in the follow-up period for persistent pain or limitation. Viscosupplementation is an effective therapeutic strategy in early stages of haemophilic arthropathy, with no complications and long-term good clinical results.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21951693     DOI: 10.1111/j.1365-2516.2011.02654.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  2 in total

Review 1.  [Conservative treatment options for arthritis of the ankle : What is possible, what is effective?]

Authors:  Jörg Jerosch
Journal:  Unfallchirurg       Date:  2022-01-18       Impact factor: 1.000

2.  Hip Arthropathy in Haemophilia.

Authors:  Christian Carulli; Anna Rosa Rizzo; Massimo Innocenti
Journal:  J Clin Med       Date:  2017-04-08       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.